Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies

n/

As atitudes dos professores do 1º, 2º e 3º ciclos do ensino básico face à inclusão de alunos com a síndrome de Asperger no ensino regular

A incessante procura de conhecer e perceber o Ser Humano, leva os cientistas a descobrir os processos psicológicos do Homem. A Síndrome de Asperger é uma categoria recente da investigação científica e ainda existe pouca informação relativamente a este assunto. As crianças/jovens com a Síndrome de Asperger não apresentam qualquer atraso no desenvolvimento da fala ou cognitivo porém é importante que esta receba uma educação especializada o mais cedo possível. (Teixeira, s.d.) Actualmente, uma das metas da escola, é levar aos alunos a aprender as normas da cultura onde encontram-se inseridos (solidariedade, respeito, cooperação…) mas também deve dar condições para que construam e interiorizem tais valores. O direito a uma igualdade de oportunidades exige da escola as melhores condições possíveis e profissionais cada vez mais qualificados para a formação de alunos que necessitam de uma educação especial. Assim é necessário conhecer as estratégias de ensino individual e transmitir aos alunos certas ferramentas para que estes recebam um ensino adequado à sua patologia. Os professores têm um papel importante neste processo, pois são os responsáveis na formação do indivíduo, são estes que fornecem-lhe as ferramentas/conhecimentos necessários para o convívio em sociedade. (Guimarães, s.d.) O presente estudo propõe-se descrever as atitudes dos professores do 1º, 2º e 3º ciclos do ensino básico face à inclusão de alunos com a Síndrome de Asperger no ensino regular. O objectivo do trabalho consiste em saber quais as variáveis que influenciam as atitudes dos professores face à inclusão de alunos com a Síndrome de Asperger, tentando relacionar o nível de ensino (1º, 2º e 3º ciclos) com as atitudes mais ou menos favoráveis apresentadas pelos docentes

Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children

<p>Abstract</p> <p>Background</p> <p>Influenza vaccination in infants and children with existing health complications is current practice in many countries, but healthy children are also susceptible to influenza, sometimes with complications. The under-recognised burden of disease in young children is greater than in elderly populations and the number of paediatric influenza cases reported does not reflect the actual frequency of influenza.</p> <p>Discussion</p> <p>Vaccination of healthy children is not widespread in Europe despite clear demonstration of the benefits of vaccination in reducing the large health and economic burden of influenza. Universal vaccination of infants and children also provides indirect protection in other high-risk groups in the community. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the vaccination of infants and children against influenza. The aim of CEVAG is to encourage the efficient and safe use of vaccines to prevent and control infectious diseases.</p> <p>Summary</p> <p>CEVAG recommends the introduction of universal influenza vaccination for all children from the age of 6 months. Special attention is needed for children up to 60 months of age as they are at greatest risk. Individual countries should decide on how best to implement this recommendation based on their circumstances.</p

Comparative epidemiologic characteristics of pertussis in 10 Central and Eastern European countries, 2000-2013

Publisher Copyright: © 2016 Heininger et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.We undertook an epidemiological survey of the annual incidence of pertussis reported from 2000 to 2013 in ten Central and Eastern European countries to ascertain whether increased pertussis reports in some countries share common underlying drivers or whether there are specific features in each country. The annual incidence of pertussis in the participating countries was obtained from relevant government institutions and/or national surveillance systems. We reviewed the changes in the pertussis incidence rates in each country to explore differences and/or similarities between countries in relation to pertussis surveillance; case definitions for detection and confirmation of pertussis; incidence and number of cases of pertussis by year, overall and by age group; population by year, overall and by age group; pertussis immunization schedule and coverage, and switch from whole-cell pertussis vaccines (wP) to acellular pertussis vaccines (aP). There was heterogeneity in the reported annual incidence rates and trends observed across countries. Reported pertussis incidence rates varied considerably, ranging from 0.01 to 96 per 100,000 population, with the highest rates generally reported in Estonia and the lowest in Hungary and Serbia. The greatest burden appears for the most part in infants (<1 year) in Bulgaria, Hungary, Latvia, Romania, and Serbia, but not in the other participating countries where the burden may have shifted to older children, though surveillance of adults may be inappropriate. There was no consistent pattern associated with the switch from wP to aP vaccines on reported pertussis incidence rates. The heterogeneity in reported data may be related to a number of factors including surveillance system characteristics or capabilities, different case definitions, type of pertussis confirmation tests used, public awareness of the disease, as well as real differences in the magnitude of the disease, or a combination of these factors. Our study highlights the need to standardize pertussis detection and confirmation in surveillance programs across Europe, complemented with carefully-designed seroprevalence studies using the same protocols and methodologies.publishersversionPeer reviewe

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine:a pooled post-hoc analysis of two parallel randomized trials

In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. Vaccine efficacy and safety were evaluated post-hoc in the pooled (ZOE-50/70) population according to the number and type of selected medical conditions present at enrollment. At enrollment, 82.3% of RZV and 82.7% of placebo recipients reported ≥1 of the 15 selected medical conditions. Efficacy against HZ ranged from 84.5% (95% Confidence Interval [CI]: 46.4–97.1) in participants with respiratory disorders to 97.0% (95%CI: 82.3–99.9) in those with coronary heart disease. Moreover, efficacy remained >90% irrespective of the number of selected medical conditions reported by a participant. As indicated by the similarity of the point estimates, this post-hoc analysis suggests that RZV efficacy remains high in all selected medical conditions, as well as with increasing number of medical conditions. No safety concern was identified by the type or number of medical conditions present at enrollment

Influenza vaccination in the elderly

Seasonal influenza is a prevalent and serious annual illness resulting in widespread morbidity and economic disruption throughout the population; the elderly and immunocompromised are particularly vulnerable to serious sequelae and mortality. The changing demographics worldwide to an aging society have important implications for public health policy and pharmaceutical innovations. For instance, primary prevention via immunization is effective in reducing the burden of influenza illness among the elderly. However, the elderly may be insufficiently protected by vaccination due to the immunosenescence which accompanies aging. In addition, vaccine hesitancy among the younger populations increases the likelihood of circulating infectious diseases, and thus concomitant exposure. While it is clear that the development of more immunogenic vaccines is an imperative and worthy endeavor, clinical trials continue to demonstrate that the current influenza vaccine formulation remains highly effective in reducing morbidity and mortality when well matched to circulating strains

Chripka - moznosti prevence ockovanim

Influenza is an illness, which doesn't attract our attention at first sight by anything interesting or new. After all we meet influenza every year in the winter month, we know its causative agent, the clinical picture, and we know that the causal therapy possibilities are limited. In reality, also prevention in the form of vaccination has not been generally trusted. The presented work demonstrates the risks and hidden secrets of that disease, both on the basis of historical data, and knowledge of the contemporary literature. The work evaluates immunogenicity and reactogenicity of vaccines against influenza, which are within easy reach on the Czech market. It compares properties of the split and subunit vaccines, and analyzes the data obtained in a clinical trial carried out in 375 healthy volunteers aged 18-60 years in the season of 1998-1999. The work compares the results of previous clinical studies. At the same time it assesses also the vaccination efficacy. Incidence of influenzal symptomatology is observed in 375 vaccinated and 340 non-vaccinated subjects. Based on results, the author tries to answer some questions connected with vaccination against influenza, and to disprove myths about pointlessness and inefficacy of the influenza prevention in the form of vaccinationAvailable from STL Prague, CZ / NTK - National Technical LibrarySIGLECZCzech Republi